Researchers may have uncovered the mechanisms behind conventional immunotherapy resistance as well as the efficacy of adoptive therapy in metastatic uveal melanoma...
In a phase II trial (NRG Oncology/GOG Study 279) reported in the Journal of Clinical Oncology, Horowitz et al found that concurrent cisplatin, gemcitabine...
In the phase II PHERGain trial reported in The Lancet, Pérez-García et al found that a positron-emission tomography (PET)-based, pathologic complete response...
Success stories in research, advocacy, and education from low- and middle-income countries deserve international recognition to motivate the next generation...
In the phase II acelERA BC trial reported in the Journal of Clinical Oncology, Miguel Martín, MD, PhD, and colleagues found that the selective estrogen receptor (ER)...
As reported in the Journal of Clinical Oncology by Karyn A. Goodman, MD, and colleagues, mature results of the phase II CALGB 80803/Alliance trial indicated that treatment guided by early positron-emission tomography (PET) assessment of response to induction neoadjuvant chemotherapy improved...
A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer. “The goal was to investigate the genetic underpinnings of different mole classes, or...
As reported in The Lancet Oncology by Meletios A. Dimopoulos, MD, and colleagues, the phase III APOLLO trial has shown significantly improved progression-free survival with the addition of subcutaneous daratumumab to pomalidomide/dexamethasone in patients with previously treated multiple myeloma....
As reported in The New England Journal of Medicine by Dean F. Bajorin, MD, and colleagues, an interim analysis of the phase III CheckMate 274 trial has shown improved disease-free survival with adjuvant nivolumab vs placebo among all patients with high-risk muscle-invasive urothelial carcinoma who...
In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...
In the European phase II PHERGain study reported in The Lancet Oncology, Pérez-García et al found that an F-18 fluorodeoxyglucose positron-emission tomography (F-18 FDG-PET) response–based strategy may be able to identify patients with HER2-positive early breast cancer who may benefit from...
In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...